Benefits Confirmed of Adjuvanted Seasonal Influenza Vaccines

In COVID-19, Latest News by Precision Vaccinations

A systematic review and meta-analysis presented at the European Scientific Working Group on Influenza virtual conference on December 7, 2020, confirmed the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.
As announced by Seqirus, the results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters. 

Read More